Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TPMT | P51580 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.46 |
| ▸ | TUBB | P07437 | 3/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290542 | 0.88 | LMNA (0.69) | LMNATPMTKMT2AMEN1ALDH1A1 | |
| SCHEMBL2796551 | 0.88 | LMNA (0.52) | LMNATPMTALDH1A1MAPTTUBB1 | |
| SCHEMBL24106215 | 0.87 | LMNA (0.55) | LMNATPMTKMT2AMEN1HTT | |
| Hydrochloric Acid SCHEMBL29142671 | 0.86 | LMNA (0.67) | LMNATPMTKMT2AMEN1ALDH1A1 | |
| SCHEMBL3355977 | 0.85 | TPMT (0.68) | LMNATPMTKMT2AMEN1ALDH1A1 | |
| SCHEMBL14218378 | 0.83 | TPMT (0.47) | LMNATPMTKMT2AMEN1ALDH1A1 | |
| SCHEMBL24425750 | 0.83 | KMT2A (0.54) | LMNATPMTKMT2AMEN1ALDH1A1 | |
| SCHEMBL801824 | 0.82 | LMNA (0.62) | LMNATPMTKMT2AMEN1ALDH1A1 | |
| SCHEMBL12245712 | 0.81 | TPMT (0.73) | LMNATPMTKMT2AMEN1HTT | |
| SCHEMBL2978683 | 0.81 | LMNA (0.50) | LMNATPMTALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | VERU INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | VERU INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20230234963-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2023-07-27 | — | — | US | disclosed |
| US-11648236-B2 | Methods of treating coronavirus | VERU INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170158707-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2017-06-08 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| EP-0091302-A1 | Beta-lactam derivatives | BEECHAM GROUP PLC (GB) | 1983-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | LMNA 3427/4885TPMT 1757/4885KMT2A 2242/4885 |
| US-20170158707-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | AHR, IL23R, IL2RA | LMNA 4543/4885TPMT 327/4885KMT2A 1625/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | LMNA 3427/4885TPMT 1757/4885KMT2A 2242/4885 |
| US-20230321045-A1 | METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS | TUBB3, TUBB1, TUBB | LMNA 588/4885TPMT 1668/4885KMT2A 3124/4885 |
| US-20230265081-A1 | METHODS OF TREATING CORONAVIRUS | TUBB3, TUBB1, TUBB | LMNA 1035/4885TPMT 519/4885KMT2A 3808/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | LMNA 3427/4885TPMT 1757/4885KMT2A 2242/4885 |
| US-20230234963-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | AHR, IL23R, IL2RA | LMNA 4543/4885TPMT 327/4885KMT2A 1625/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | LMNA 3427/4885TPMT 1757/4885KMT2A 2242/4885 |
| US-11648236-B2 | Methods of treating coronavirus | TUBB3, TUBB1, TUBB | LMNA 1035/4885TPMT 519/4885KMT2A 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.